The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 14, 2023
Filed:
Sep. 25, 2018
Inserm (Institut National DE LA Santé ET DE LA Recherche Médicale), Paris, FR;
Université D'aix Marseille, Marseilles, FR;
Centre National DE LA Recherche Scientifique (Cnrs), Paris, FR;
Université Claude Bernard—lyon 1, Villeurbanne, FR;
Centre Leon Berard, Lyons, FR;
Philippe Naquet, Marseilles, FR;
Franck Galland, Marseilles, FR;
Virginie Millet, Marseilles, FR;
Jean-Yves Blay, Lyons, FR;
Caroline Giessner, Marseilles, FR;
INSERM (Institut National de la Santé et de la Recherche Médicale), Paris, FR;
Université d'Aix Marseille, Marseilles, FR;
Centre National de la Recherche Scientifique (CNRS), Paris, FR;
Université Claude Bernard, Lyons, FR;
Centre Leon Bernard, Lyons, FR;
Abstract
Sarcomas are rare malignant tumors arising from the mesenchymal tissues at all body sites. The inventors show that in a mouse model of p16/p19 deficiency prone to tumor development, the absence of the mouse pantetheinase Vnn1 enhances the frequency of aggressive fibrosarcomas. They also show that reintroduction of a catalytically active form of the Vnn1 pantetheinase limits tumor growth in vivo. Interestingly, VNN1 expression in human sarcomas is associated with reduced aggressiveness and lower risk of metastatic relapse in patients. In conclusion, Vnn1 represents a novel marker of sarcoma and may modulate tumor aggressiveness by sustaining myofibroblast cell differentiation, thereby limiting evolution towards undifferentiated tumors. The present invention relates to the use of Vnn1 as a biomarker and a therapeutic target in sarcomas.